A multidisciplinary expert panel favoured prostate-specific membrane antigen positron emission tomography/computed tomography for primary staging of unfavourable intermediate- and high-risk prostate cancer and for selecting treatments in metastatic hormone-sensitive prostate cancer. Here, FOLH1 is linked to prostate carcinoma.